Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancer
Latest Information Update: 20 Apr 2022
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2021 Planned End Date changed from 30 Sep 2021 to 31 Jul 2022.
- 16 Sep 2020 New trial record